Spyre Therapeutics, Inc. SYRE Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s cumulative cost basis?
- Spyre Therapeutics, Inc. (SYRE) reported cumulative cost basis of $645.05M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s cumulative cost basis changed year-over-year?
- Spyre Therapeutics, Inc.'s cumulative cost basis increased by 25.1% year-over-year, from $515.68M to $645.05M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s cumulative cost basis?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s cumulative cost basis has grown at a 217.8% compound annual growth rate (CAGR), from $20.88M to $669.94M.